📰 Newspapers

Merck’s drug prolongs survival in advanced stomach, esophageal cancers in trial

Merck’s drug prolongs survival in advanced stomach, esophageal cancers in trial

Merck announced that its experimental cancer drug, sacituzumab tirumotecan, extends the survival of patients with advanced stomach and esophageal cancers compared to standard treatments.

NEW JERSEY: Merck said on Friday that its experimental cancer drug helped patients with advanced stomach and esophageal cancers live longer than standard treatment options in a late-stage trial.

The trial compared the drug, sacituzumab tirumotecan, also known as sac-TMT, to physician-selected chemotherapy, including trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel.

The trial enrolled 473 patients whose cancer could not be removed by surgery and whose disease had progressed after at least two earlier treatments.

Sac-TMT is an antibody-drug conjugate, a type of targeted cancer therapy designed to deliver cancer-killing drugs directly to tumor cells while minimizing damage to healthy tissue.

Merck said sac-TMT met the trial’s main goal of improving overall survival but did not disclose detailed data, which it plans to present at a future medical meeting.

The study, however, did not meet its secondary goal of delaying cancer progression, as measured by an independent review. Merck said the drug had no new safety concerns.

The results mark another positive late-stage trial for sac-TMT, which Merck licensed from China’s Kelun-Biotech for markets outside Greater China.

Merck is currently testing sac-TMT for multiple cancers, including lung, breast and gastrointestinal tumors.

In brief

NEW JERSEY: Merck said on Friday that its experimental cancer drug helped patients with advanced stomach and esophageal cancers live longer than standard treatment options in a late-stage trial. Merck said the drug had no new safety concerns. The results mark another positive late-stage trial for sac-TMT, which Merck licensed from China’s Kelun-Biotech for markets outside Greater China.

This is the opening of the story, shared with credit to Arab News. The rest of the report — with every detail — continues on the publisher’s website.

Continue reading at Arab News ↗

Cookie settings

Choose which cookies we may use. You can change this at any time from Cookie settings in the footer. Details of each cookie are in the Cookie Policy.

Strictly necessary

Needed for sign-in, security, payments and remembering these choices. Always on.

Preferences

Remember settings such as dark mode.

Analytics & performance

Help us count visits, understand which pages, devices and countries our readers use, and measure how well the site performs – anonymous and aggregated.

Advertising & marketing

Lets advertising partners show and personalise adverts, measure impressions, clicks and visits, prevent ad fraud and pay us – this is how the free site is funded.

🔔 News notifications

Get headlines from NewsHub on this device — even when the site is closed.

You can switch this off at any time. Works on Android, Windows, Mac and Linux browsers; on iPhone/iPad add the site to your Home Screen first.